Evidence map›Paper›PMID 34864785›Full record

Trial reportJournal of addiction medicine

The Relationship Between Reductions in WHO Risk Drinking Levels During Treatment and Subsequent Healthcare Costs for the ACTIVE Workgroup.

Arnie P Aldridge, Gary A Zarkin, William N Dowd, Katie Witkiewitz, Deborah S Hasin, Stephanie S O'Malley, Keith Isenberg, Raymond F Anton

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Arnie P AldridgeFrom the Behavioral Health Research Division, RTI International, NC (APA, GAZ, WND), Department of Psychology, University of NewMexico, 2650 Yale SE MSC11-6280, Albuquerque, NM (KW), Department of Epidemiology, Columbia University, New York, NY (DSH), Department of Medicine, Yale University, Connecticut Mental Health Center, New Haven, CT (SSO), Anthem Inc., Indianapolis, IN (KI), Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC (RFA).
Gary A Zarkin
William N Dowd
Katie Witkiewitz
Deborah S Hasin
Stephanie S O'Malley
Keith Isenberg
Raymond F Anton
School of the Art Institute of Chicago · USConnecticut Mental Health Center · US

Funding

Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints - Administrative SupplementR01AA025309 · NIAAA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI HASIN, DEBORAH S · 2016 to 2021
$925k
Improving Models of Alcohol Consumption Mismeasurement and Burden of DiseaseR01AA027796 · NIAAA · RESEARCH TRIANGLE INSTITUTE · PI ALDRIDGE, ARNIE PAUL · 2019 to 2021
$775k
The Long-term Costs and Benefits of Alcohol TreatmentsR01AA024423 · NIAAA · RESEARCH TRIANGLE INSTITUTE · PI BARBOSA, CAROLINA · 2016 to 2018
$692k
NIAAA NIH HHS R01 AA024423NIAAA NIH HHS R01 AA025309NIAAA NIH HHS R01 AA027796
6 · The paper itself

Abstract

backgroundAbstinence has historically been considered the target outcome for alcohol use disorder (AUD) treatment, yet recent work has found drinking reductions after AUD treatment, as measured by World Health Organization (WHO) risk drinking levels, are associated with meaningful improvements in functioning, physical health, and quality of life.

objectivesThis study extends previous analyses of AUD treatment outcomes by estimating the association between changes in WHO risk drinking levels (very high, high, medium, and low, based on average daily alcohol consumption) and healthcare costs.

methodsSecondary data analysis of the COMBINE study, a multisite randomized clinical trial of acamprosate, naltrexone and behavioral interventions for AUD. Generalized gamma regression models were used to estimate relationships between WHOrisk drinking level reductions over the course of treatment and healthcare costs in the year after treatment (N = 964) and up to 3 years following treatment (N = 651).

resultsSustainedWHOrisk drinking reductions of 2 or more levels throughout treatment were associated with 52.0% lower healthcare costs ( P < 0.001) in the year following treatment, and 44.0% lower costs ( P < 0.0025) over 3 years. A reduction of exactly 1 level was associated with 34.8% lower costs over 3 years, which was not significant ( P = 0.05). Cost reductions were driven by lower inpatient behavioral health and emergency department utilization.

conclusionsReduction in WHO risk drinking levels of at least 2 levels was associated with lower healthcare costs over 1 and 3 years. Our results add to literature showing drinking reductions are associated with improvement in health.

Indexed as

AlcoholismQuality of LifeAlcohol DrinkingHealth Care CostsHumansTreatment OutcomeWorld Health Organization

Identifiers

PMID34864785
PMCPMC9163210
OpenAlexW4200351444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.